MSD’s Keytruda significantly extended overall survival when used as monotherapy for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in patients expressing PD-L1.
ViiV Healthcare has unveiled positive clinical data for two two-drug HIV regimens ay the 22nd International AIDS conference in Amsterdam, showing long-term efficacy and non-inferiority to a current standard of care.
AbbVie and Neurocrine have announced the US approval of Orilissa, the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe endometriosis pain.
The government has confirmed that boys in England will be vaccinated against the human papilloma virus in line with recent recommendations from the Joint Committee on Vaccination and Immunisation (JCVI).
US regulatory advisors are questioning the effectiveness of GlaxoSmithKline’s biologic Nucala as a treatment for patients experiencing a sudden worsening of chronic obstructive pulmonary disorder (COPD).
Shares in UK-based clinical-stage biopharm PureTech Health have been given a boost by news that Roche has signed up to advance its exosome platform technology in a deal potentially worth more than $1 billion.